High Tide's German Subsidiary Remexian Pharma Showcases Exclusive Canadian Medical Cannabis Brand Partnerships at Mary Jane Berlin 2026
High Tide Reports Second Quarter 2026 Financial Results Featuring Record Revenue of $179.3MM, and Adjusted EBITDA of $13.9MM
High Tide Reports Record Quarterly Distribution of 7.6 Tonnes of Medical Cannabis Through Remexian Pharma GmbH, Accelerating German Market Leadership
High Tide Executes a Term Sheet for $40MM of Credit Facilities with a Big 5 Canadian Chartered Bank As its New Senior Lender
High Tide Subsidiary NuLeaf Naturals Pursues Participation in U.S. Medicare CBD Pilot Launching Today
High Tide Reports First Quarter 2026 Financial Results Featuring Record Revenue Exceeding $700 Million Annualized
Tartisan Nickel Corp. Acquires Nickel-Copper Claims, Outlines 2026 Work Program at Turtle Pond, Northwestern Ontario
Charbone Annonce Les Resultats De L'assemblee Generale Annuelle Et Extraordinaire Des Actionnaires Et L'octroi D'attributions D'actions
